Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

19941,430 citationsJournal Articlebronze Open Access

Authors

Robert J. Mayer · Harvard University

Roger B. Davis

Charles A. Schiffer · University of Maryland, Baltimore

Deborah Berg · Harvard University

Bayard L. Powell

Philip Schulman

George Omura · University of Alabama at Birmingham

Joseph O. Moore · Duke Medical Center

Abstract

These data support the concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger. The results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.

Topics & Keywords

Acute Myeloid Leukemia Research Acute Lymphoblastic Leukemia research Myeloproliferative Neoplasms: Diagnosis and Treatment

Publication Details

Published in: New England Journal of Medicine

Volume 331, Issue 14, pp. 896-903

DOI: 10.1056/nejm199410063311402

Field-Weighted Citation Impact: 22.86

Command Palette

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

Authors

Abstract

Topics & Keywords

Publication Details